More than 97,000 patients receiving antiretrovirals as a treatment for HIV in Mexico are guaranteed delivery of their drugs, according to the National Center for Prevention and Control of HIV and AIDS (CENSIDA).
The agency also reported that there is enough supply to take care of those diagnosed with the disease, while noting that the process of purchasing these drugs for 2019 "has not affected the capital injection or compromised the health of the people they are receiving them."
He pointed out that even if the purchasing process is still open, drug transformation processes, assignment of treatment systems and information for prescription, modification and delivery are performed.
Likewise, he said there are mechanisms to maintain access to antiretroviral drugs throughout the country, either through direct purchases, open international public bidding or other public health support.
CENSIDA pointed out that the drugs acquired through tenders are covered until the beginning of June 2019.
Even if it comes to patent medicines, there is enough supply to meet the demand up to the beginning of May 2019.
He said it is expected that the first delivery of antiretroviral agents acquired through direct delivery will be initiated this month so that treatment of HIV-infected patients treated by the Ministry of Health is avoided.
Similarly, it was announced that on March 31, the exercise of the antiretroviral drug purchase agreements purchased through the catastrophic spending fund 2018-2019 ended.
In Mexico, according to Censida, from 1983 to March 2018, 196,227 cases have been reported in the country.
Until 2017, coverage in the country was 65% in the diagnosis, 61% in treatment and 51% in viral suppression, and it is expected that 80% of the diagnosed persons will be reached nearly 90 years closer to the goal 90 -90-90 of the World Health Organization (WHO) .